Inhibikase Therapeutics (IKT) Return on Capital Employed (2021 - 2026)
Inhibikase Therapeutics' (IKT) quarterly Return on Capital Employed came in at 32.19% in Q1 2026, up 1151.0% year-on-year from 2.57% in Q1 2025, and up 24.39% on a QoQ basis from 42.57% in Q4 2025.
Inhibikase Therapeutics (IKT) Return on Capital Employed (2021 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 6 years of Return on Capital Employed data on file, last reported at 32.19% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 1151.0% year-over-year to 32.19% in Q1 2026; TTM through Mar 2026 was 32.19%, a 1151.0% increase from a year earlier, with the FY2025 full-year figure at 39.49%, up 1463.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 32.19%, up from 42.57% in the prior quarter.
- Over the last five years, Return on Capital Employed for IKT reached as high as 32.19% in Q1 2026 and fell as low as 1184.15% in Q3 2024.
- Historically, Return on Capital Employed has averaged 173.62% across 5 years, with a median of 76.21% in 2023.
- Across the five-year window, Return on Capital Employed sank 106890 bps in 2024 and surged 111821 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 78.6% in 2022, then slumped by 100 bps to 157.5% in 2023, then jumped by 62 bps to 59.87% in 2024, then gained by 29 bps to 42.57% in 2025, then advanced by 24 bps to 32.19% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 32.19% in Q1 2026, 42.57% in Q4 2025, and 65.95% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Inhibikase Therapeutics | 55.25 Mn | -115.12 Mn | - | -32.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.19% |
| Dec 31, 2025 | -42.57% |
| Sep 30, 2025 | -65.95% |
| Jun 30, 2025 | -53.39% |
| Mar 31, 2025 | -43.70% |
| Dec 31, 2024 | -59.87% |
| Sep 30, 2024 | -1,184.15% |
| Jun 30, 2024 | -304.43% |
| Mar 31, 2024 | -235.64% |
| Dec 31, 2023 | -157.50% |
| Sep 30, 2023 | -115.25% |
| Jun 30, 2023 | -87.76% |
| Mar 31, 2023 | -76.21% |
| Dec 31, 2022 | -78.60% |
| Sep 30, 2022 | -67.09% |
| Dec 31, 2021 | -36.81% |
| Sep 30, 2021 | -24.37% |
| Jun 30, 2021 | -24.86% |
| Mar 31, 2021 | -50.35% |